Search research articles
Contact Us
Filters
Showing results (101-110 of 130) with videos related to
Page
of 13
Sort By:
Gynecologic Oncology
|
September 15, 2021
Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL)
Stephanie Gaillard, Ana Oaknin, Isabelle Ray-Coquard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 23, 2009
Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors
Ruth Plummer, Laura Vidal, Melanie Griffin, et al.
Clinical and Experimental Rheumatology
|
January 24, 2020
Toll-like receptor 3 increases antigen-presenting cell responses to a pro-apoptotic stimulus, yet does not contribute to systemic lupus erythematosus genetic susceptibility
Aurélie De Groof, Julie Ducreux, Laura Vidal-Bralo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 21, 2010
Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers
Kevin J Harrington, Eleni M Karapanagiotou, Victoria Roulstone, et al.
International Journal of Molecular Sciences
|
February 27, 2026
Immune Checkpoint Signatures Reveal Stage-Specific Biomarkers for High-Activity Multiple Sclerosis
MariPaz López-Molina, Gabriel Torres Iglesias, Laura Vidal, et al.
Open Heart
|
June 26, 2025
First year after surgery is the optimal period to define early prosthetic valve endocarditis: a cohort study
Jorge Calderón-Parra, Francesc Escrihuela, Guillermo Cuervo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 12, 2008
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors
Josep Tabernero, Federico Rojo, Emiliano Calvo, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 2, 2014
Structure-activity relationships (SAR) and structure-kinetic relationships (SKR) of bicyclic heteroaromatic acetic acids as potent CRTh2 antagonists III: the role of a hydrogen-bond acceptor in long receptor residence times
Juan Antonio Alonso, Miriam Andrés, Mónica Bravo, et al.
Journal of Clinical Medicine
|
May 14, 2022
Infective Endocarditis in Diabetic Patients: A Different Profile with Prognostic Consequences
María Isabel Biezma, Patricia Muñoz, Sofía De la Villa, et al.
Immunotherapy
|
September 5, 2025
First-line pembrolizumab for metastatic NSCLC in lower-middle-income countries: bridging the efficacy-effectiveness gap
Ullas Batra, Mansi Sharma, Alexis Andrew Miller, et al.
Page
of 13
Search research articles
Search
Showing results (101-110 of 130) with videos related to
Sort By:
Page
of 13
Gynecologic Oncology
|
September 15, 2021
Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL)
Stephanie Gaillard, Ana Oaknin, Isabelle Ray-Coquard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 23, 2009
Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors
Ruth Plummer, Laura Vidal, Melanie Griffin, et al.
Clinical and Experimental Rheumatology
|
January 24, 2020
Toll-like receptor 3 increases antigen-presenting cell responses to a pro-apoptotic stimulus, yet does not contribute to systemic lupus erythematosus genetic susceptibility
Aurélie De Groof, Julie Ducreux, Laura Vidal-Bralo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 21, 2010
Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers
Kevin J Harrington, Eleni M Karapanagiotou, Victoria Roulstone, et al.
International Journal of Molecular Sciences
|
February 27, 2026
Immune Checkpoint Signatures Reveal Stage-Specific Biomarkers for High-Activity Multiple Sclerosis
MariPaz López-Molina, Gabriel Torres Iglesias, Laura Vidal, et al.
Open Heart
|
June 26, 2025
First year after surgery is the optimal period to define early prosthetic valve endocarditis: a cohort study
Jorge Calderón-Parra, Francesc Escrihuela, Guillermo Cuervo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 12, 2008
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors
Josep Tabernero, Federico Rojo, Emiliano Calvo, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 2, 2014
Structure-activity relationships (SAR) and structure-kinetic relationships (SKR) of bicyclic heteroaromatic acetic acids as potent CRTh2 antagonists III: the role of a hydrogen-bond acceptor in long receptor residence times
Juan Antonio Alonso, Miriam Andrés, Mónica Bravo, et al.
Journal of Clinical Medicine
|
May 14, 2022
Infective Endocarditis in Diabetic Patients: A Different Profile with Prognostic Consequences
María Isabel Biezma, Patricia Muñoz, Sofía De la Villa, et al.
Immunotherapy
|
September 5, 2025
First-line pembrolizumab for metastatic NSCLC in lower-middle-income countries: bridging the efficacy-effectiveness gap
Ullas Batra, Mansi Sharma, Alexis Andrew Miller, et al.
Page
of 13